Cancer Therapy
Clinical & Experimental Immunology
Continuing on the theme of cancer therapy,
Martinelli et al. discuss the mechanisms of epidermal growth factor receptor (EGFR)-specific monoclonal antibodies in cancer therapy. EGFR, a transmembrane tyrosine kinase receptor, is the first molecular target against which monoclonal antibodies have been developed for cancer therapy. The authors focus on two recently introduced EGFR monoclonal antibodies, cetuximab and panitumumab, designed for the treatment of metastatic colorectal and, head and neck cancer.